Coronavirus & secondaries: Niche dilemmas
Anecdotal feedback from secondaries professionals reveals a quick onset of stagnation in the market due to COVID-19. Creative workarounds are not impossible, but almost
There are two main channels of secondaries deal flow: hot tickets in the form desirable fund positions and portfolio companies where new investors clamor for exposure and the various situations where existing...
More on Secondaries
Latest News
Warburg Pincus leads Series C for China AI drug developer
Insilico Medicine, which leverages artificial intelligence (AI) technology to speed up the drug development process, has closed a $255 million Series C funding round led by Warburg Pincus.
PE investors agree $5.7b 51job take-private
A consortium led by DCP Capital Partners has finalized terms for a $5.7 billion privatization of US-listed Chinese online recruitment platform 51job.
Chinese drug developer Abbisko files for HK IPO
PE-backed Abbisko Therapeutics, which focuses on the discovery and development of innovative and differentiated small molecule oncology therapies, has filed for a Hong Kong IPO.